Relevant bibliographies by topics / Tumoren. Angiogenese. Inhibitie

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Tumoren. Angiogenese. Inhibitie'

Author: Grafiati
Published: 4 June 2021
Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Tumoren. Angiogenese. Inhibitie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Tumoren. Angiogenese. Inhibitie"

1

Bodei, Lisa, and Wolfgang Weber. "Theranostik von neuroendokrinen Tumoren." Der Nuklearmediziner 42, no. 01 (2019): 46–58. http://dx.doi.org/10.1055/a-0807-3499.

Full text
Abstract:
ZusammenfassungNeuroendokrine Tumore sind eine heterogene Gruppe von Erkrankungen, die häufig spezifische Rezeptoren, Transporter und Enzyme exprimieren, die für die nuklearmedizinische Bildgebung und Therapie eingesetzt werden können. Insbesondere radioaktiv markierte Liganden der Somatostatinrezeptoren haben sich dabei als effektiv erwiesen. Die medikamentöse Therapie von neuroendokrinen Tumoren ist abhängig vom histologischen Differenzierungsgrad und der Tumorlokalisation. Durch randomisierte Studien wurde die Effektivität von Somatostatinanaloga nicht nur für die Behandlung von Symptomen,
APA, Harvard, Vancouver, ISO, and other styles
2

Cuevas, Pedro, Fernando Carceller, Diana Reimers, Begoña Cuevas, Rosa M. Lozano, and G. Giménez-Gallego. "Inhibition of intra-tumoral angiogenesis and glioma growth by the fibroblast growth factor inhibitor 1,3,6-naphthalenetrisulfonate." Neurological Research 21, no. 5 (1999): 481–87. http://dx.doi.org/10.1080/01616412.1999.11740962.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Miyake, Makito, Steve Goodison, Evan Gomes, et al. "Induction of endothelial proliferation and angiogenesis through activating the ERK1/2/EGF pathway mediate by CXC chemokine receptor 2 by chemokine (C-X-C motif) ligand 1." Journal of Clinical Oncology 31, no. 6_suppl (2013): 138. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.138.

Full text
Abstract:
138 Background: Endothelial cell growth and proliferation are critical for tumoral angiogenesis. We report here that blockade of Chemokine (C-X-C motif) ligand 1 (CXCL1) results in reduction of human endothelial cell proliferation and its ability to induce angiogenesis. Methods: Two human endothelial cell lines, HUVEC and HDMEC, were used in the in vitro assays. Proliferation assay and matrigel tube formation assay were performed to test the inhibitory effect of anti-CXCL antibody on the activity of endothelial cells in vitro. Matrigel plug assay in nude mice was performed to test the in vivo
APA, Harvard, Vancouver, ISO, and other styles
4

Birbrair, Alexander, Tan Zhang, Zhong-Min Wang, et al. "Type-2 pericytes participate in normal and tumoral angiogenesis." American Journal of Physiology-Cell Physiology 307, no. 1 (2014): C25—C38. http://dx.doi.org/10.1152/ajpcell.00084.2014.

Full text
Abstract:
Tissue growth and function depend on vascularization, and vascular insufficiency or excess exacerbates many human diseases. Identification of the biological processes involved in angiogenesis will dictate strategies to modulate reduced or excessive vessel formation. We examine the essential role of pericytes. Their heterogeneous morphology, distribution, origins, and physiology have been described. Using double-transgenic Nestin-GFP/NG2-DsRed mice, we identified two pericyte subsets. We found that Nestin-GFP−/NG2-DsRed+ (type-1) and Nestin-GFP+/NG2-DsRed+ (type-2) pericytes attach to the walls
APA, Harvard, Vancouver, ISO, and other styles
5

Ribeiro, Aline Lopes, Carolini Kaid, Patrícia B. G. Silva, Beatriz A. Cortez, and Oswaldo Keith Okamoto. "Inhibition of Lysyl Oxidases Impairs Migration and Angiogenic Properties of Tumor-Associated Pericytes." Stem Cells International 2017 (2017): 1–10. http://dx.doi.org/10.1155/2017/4972078.

Full text
Abstract:
Pericytes are important cellular components of the tumor microenviroment with established roles in angiogenesis and metastasis. These two cancer hallmarks are modulated by enzymes of the LOX family, but thus far, information about LOX relevance in tumor-associated pericytes is lacking. Here, we performed a comparative characterization of normal and tumoral pericytes and report for the first time the modulatory effects of LOX enzymes on activated pericyte properties. Tumoral pericytes isolated from childhood ependymoma and neuroblastoma specimens displayed angiogenic properties in vitro and exp
APA, Harvard, Vancouver, ISO, and other styles
6

Kim, Min Jeong, Anjugam Paramanantham, Won Sup Lee та ін. "Anthocyanins Derived from Vitis coignetiae Pulliat Contributes Anti-Cancer Effects by Suppressing NF-κB Pathways in Hep3B Human Hepatocellular Carcinoma Cells and In Vivo". Molecules 25, № 22 (2020): 5445. http://dx.doi.org/10.3390/molecules25225445.

Full text
Abstract:
We previously demonstrated that anthocyanins from the fruits of Vitis coignetiae Pulliat (AIMs) induced the apoptosis of hepatocellular carcinoma cells. However, many researchers argued that the concentrations of AIMs were too high for in vivo experiments. Therefore, we performed in vitro at lower concentrations and in vivo experiments for the anti-cancer effects of AIMs. AIMs inhibited the cell proliferation of Hep3B cells in a dose-dependent manner with a maximum concentration of 100 µg/mL. AIMs also inhibited the invasion and migration at 100 µg/mL concentration with or without the presence
APA, Harvard, Vancouver, ISO, and other styles
7

Ganslmayer, Marion, Christoph Herold, Matthias Ocker, John Williams, Eckhart G. Hahn, and Detlef Schuppan. "A combination therapy with a histonedeacetylase inhibitor and a angiogenesis inhibitor acts anti-tumoral in hepatomas." Journal of Hepatology 36 (April 2002): 214–15. http://dx.doi.org/10.1016/s0168-8278(02)80766-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nair, Mitra, Chelsea Bolyard, Tae Jin Lee, Balveen Kaur, and Ji Young Yoo. "Therapeutic Application of Brain-Specific Angiogenesis Inhibitor 1 for Cancer Therapy." Cancers 13, no. 14 (2021): 3562. http://dx.doi.org/10.3390/cancers13143562.

Full text
Abstract:
Brain-specific angiogenesis inhibitor 1 (BAI1/ADGRB1) is an adhesion G protein-coupled receptor that has been found to play key roles in phagocytosis, inflammation, synaptogenesis, the inhibition of angiogenesis, and myoblast fusion. As the name suggests, it is primarily expressed in the brain, with a high expression in the normal adult and developing brain. Additionally, its expression is reduced in brain cancers, such as glioblastoma (GBM) and peripheral cancers, suggesting that BAI1 is a tumor suppressor gene. Several investigators have demonstrated that the restoration of BAI1 expression i
APA, Harvard, Vancouver, ISO, and other styles
9

Pinter, Matthias, Wolfgang Sieghart, Monika Schmid, et al. "Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF‐A expression in hepatocellular carcinoma." United European Gastroenterology Journal 1, no. 4 (2013): 265–75. http://dx.doi.org/10.1177/2050640613496605.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Abula, Ayipairi, Jing Zhao, Guancheng Xu, Yijie Li, and Surong Sun. "Antitumor effect of a pyrazolone-based-complex [Cu(PMPP-SAL)(EtOH)] against murine melanoma B16 cell in vitro and in vivo." Acta Pharmaceutica 70, no. 4 (2020): 561–75. http://dx.doi.org/10.2478/acph-2020-0040.

Full text
Abstract:
AbstractPyrazolone-based derivative metal complexes were reported to have cytotoxicity in some tumor cells. In this study, the antitumor effect of [Cu(PMPP-SAL)(EtOH)] (PMPP-SAL = N-(1-phenyl-3-methyl-4-propenylidene-5-pyrazolone)- salicylidene hydrazide anion) in murine melanoma B16 cells in vitro and in vivo was investigated. The results showed that [Cu(PMPP-SAL)(EtOH)] inhibited the survival of B16 cells in vitro, and the IC50 value was superior to cisplatin (DDP) (p < 0.001). B16 cell apoptosis was significantly higher in comparison to the control group (DMSO) (p < 0.01), and cell cy
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Tumoren. Angiogenese. Inhibitie"

1

Schaft, Daisy W. J. van der. "Development of novel angiogenesis inhibitors for cancer treatment." [Maastricht : Maastricht : Universiteit Maastricht] ; University Library, Maastricht University [Host], 2002. http://arno.unimaas.nl/show.cgi?fid=7130.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Niwano, Mototaka. "The Inhibition of Tumor Growth and Microvascular Angiogenesis by the Potent Angiogenesis inhibitor, TNP-470 in Rats." Kyoto University, 1998. http://hdl.handle.net/2433/156992.

Full text
Abstract:
本文データは平成22年度国立国会図書館の学位論文(博士)のデジタル化実施により作成された画像ファイルを基にpdf変換したものである<br>Kyoto University (京都大学)<br>0048<br>新制・課程博士<br>博士(医学)<br>甲第7486号<br>医博第2039号<br>新制||医||697(附属図書館)<br>UT51-98-U153<br>京都大学大学院医学研究科分子医学系専攻<br>(主査)教授 千葉 勉, 教授 山岡 義生, 教授 今村 正之<br>学位規則第4条第1項該当
APA, Harvard, Vancouver, ISO, and other styles
3

Vitaliti, Alessandra. "Inhibition of tumor induced angiogenesis /." [S.l.] : [s.n.], 1999. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=13409.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Åkerman, Maria E. "Targeting and inhibiting tumor angiogenesis /." Diss., Connect to a 24 p. preview or request complete full text in PDF format. Access restricted to UC campuses, 2005. http://wwwlib.umi.com/cr/ucsd/fullcit?p3166405.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zieher, Heike. "Untersuchungen des Einflusses von Inhibitoren der Angiogenese und ionisierender Bestrahlung auf das Wachstumsverhalten solider Tumoren in vivo." Giessen : VVB Laufersweiler, 2007. http://geb.uni-giessen.de/geb/volltexte/2007/4714/index.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Escuin, i. Borràs Daniel. "Novel mechanistic link between microtubule disruption and inhibition of tumor angiogenesis." Doctoral thesis, Universitat Autònoma de Barcelona, 2004. http://hdl.handle.net/10803/4458.

Full text
Abstract:
L'angiogènesis, el desenvolupament de nous vasos sanguinis a partir de vasculatura preexistent, és un procés complex que involucra múltiples productes gènics expressats per diferents tipus cel.lulars, i tots ells contribueixen a una seqüència integrada de fenòmens. L'angiogènesis és necessària per tal de permetre el creixement tumoral més enllà d'una certa mida. La hipòxia, un fenomen inherent en els tumors, és un dels factors principals que desencadena el procés angiogènic. En concordança amb el fet que la hipòxia juga un paper clau en tot el procés, un nombre elevat de gens involucrats en di
APA, Harvard, Vancouver, ISO, and other styles
7

Liu, Minghui. "Gene Therapy with Interferon Alpha and the Angiogenic Inhibitor, Vasostatin, in Neuroendocrine Tumors of the Digestive System." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-7453.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Thulin, Åsa. "The Role of Histidine-rich Glycoprotein in Angiogenesis and Tumor Growth." Doctoral thesis, Uppsala universitet, Institutionen för medicinsk biokemi och mikrobiologi, 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-110829.

Full text
Abstract:
Histidine-rich glycoprotein (HRG) is a heparin-binding plasma protein modulating immune, hemostatic and vascular functions. I have studied the antiangiogenic functions of HRG in vitro and in vivo in order to understand the molecular mechanisms of action of HRG as an angiogenesis inhibitor. Angiogenesis is the formation of new blood vessels from the pre-existing vasculature. It is a central rate-limiting step of tumor development and thus a possible target for cancer therapeutics. Previous studies have shown that HRG has antiangiogenic functions in vivo and that the antiangiogenic effects are m
APA, Harvard, Vancouver, ISO, and other styles
9

Tachijian, Nataly. "The effect of deactivation or silencing of tumor stroma with angiogenesis inhibitor on malignancy of tumor metastases." Thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-445622.

Full text
Abstract:
Background: Neuroblastoma (NB) is a pediatric tumor in infants and young children. The survival rate is only around 50 percent for high-risk NB despite advanced and intense multi-modal therapy. Current research aims to find new effective treatment additional to modern therapy to improve prognosis of high-risk NB in children. As such, SU11248 may be a valuable approach for improving treatment and survival as growth factors have crucial roles in tumor growth, angiogenesis, and metastasis. Aim: The aim of this investigation was to examine tissues from SU11248 treated and nontreated tumor-bearing
APA, Harvard, Vancouver, ISO, and other styles
10

Ischenko, Ivan. "Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer." Diss., lmu, 2007. http://nbn-resolving.de/urn:nbn:de:bvb:19-64833.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Tumoren. Angiogenese. Inhibitie"

1

Woolf, Eric C., and Adrienne C. Scheck. Ketogenic Diet as Adjunctive Therapy for Malignant Brain Cancer. Edited by Jong M. Rho. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190497996.003.0013.

Full text
Abstract:
Malignant brain tumors are devastating, and increased survival requires new therapeutic modalities. Metabolic dysregulation results in an increased need for glucose in tumor cells, suggesting that reduced tumor growth could be achieved with decreased glucose availability either through pharmacological means or use of a high-fat, low-carbohydrate ketogenic diet (KD). KD provides increased blood ketones to support energy needs of normal tissues and has been shown to reduce tumor growth, angiogenesis, inflammation, peritumoral edema, migration, and invasion. Furthermore, this diet can enhance the
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Tumoren. Angiogenese. Inhibitie"

1

Schliemann, Christoph, and Dario Neri. "Antibody-Based Vascular Tumor Targeting." In Angiogenesis Inhibition. Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-78281-0_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rüegg, Curzio, and Gian Carlo Alghisi. "Vascular Integrins: Therapeutic and Imaging Targets of Tumor Angiogenesis." In Angiogenesis Inhibition. Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-78281-0_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Benson, Charlotte, and Michela Libertini. "Inhibition of Tumor Angiogenesis in GIST Therapy." In Tumor Angiogenesis. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-31215-6_19-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Benson, Charlotte, and Michela Libertini. "Inhibition of Tumor Angiogenesis in GIST Therapy." In Tumor Angiogenesis. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-33673-2_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Di Maio, Massimo, Silvia Novello, Enrica Capelletto, and Giorgio Vittorio Scagliotti. "Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer." In Tumor Angiogenesis. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-31215-6_22-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Di Maio, Massimo, Silvia Novello, Enrica Capelletto, and Giorgio Vittorio Scagliotti. "Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer." In Tumor Angiogenesis. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-33673-2_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Miller, Kathy D., Christopher J. Sweeney, and George W. Sledge. "Can tumor angiogenesis be inhibited without resistance?" In Mechanisms of Angiogenesis. Birkhäuser Basel, 2005. http://dx.doi.org/10.1007/3-7643-7311-3_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Plate, Karl H. "Control of Tumor Growth Via Inhibition of Tumor Angiogenesis." In Advances in Experimental Medicine and Biology. Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5357-1_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stöltzing, Oliver, S. A. Ahmad, W. Liu, et al. "Inhibition von Tumor-Angiogenese und Gefäßpermeabilität durch Angiopoietin-1." In Deutsche Gesellschaft für Chirurgie. Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-19024-7_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stöltzing, O., S. A. Ahmad, W. Liu, et al. "Inhibition von Tumor-Angiogenese und Gefäßpermeabilität durch Angiopoietin-1." In Zurück in die Zukunft. Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-55611-1_305.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Tumoren. Angiogenese. Inhibitie"

1

Singhal, Sharad S., James Figarola, Jyotsana Singhal, Lokesh Nagaprashantha, and Sanjay Awasthi. "Abstract 2816: 2′-Hydroxyflavanone inhibits lung cancer growth by inhibiting tumor cell proliferation and angiogenesis." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2816.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nagaprashantha, Lokesh Dalasanur, Rit Vatsyayan, Jyotsana Singhal, et al. "Abstract 3702: 2-Hydroxyflavanone inhibits renal cancer growth by inhibiting tumor cell proliferation and angiogenesis." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3702.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Akira, Hori, Shuntarou Tsuchiya, Yuichi Kakoi, Akio Mizutani, and Patrick Vincent. "Abstract 2520: TAK-733, a novel MEK1/2 inhibitor, inhibits tumor angiogenesis without affecting vascular permeability." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2520.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jiang, Bing-Hua, Ling-Zhi Liu, Lisa Jiang, Yi Jing, and Xiue Jiang. "Abstract A51: Acacetin in inhibiting tumor growth and angiogenesis." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Nov 7-10, 2010; Philadelphia, PA. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1940-6207.prev-10-a51.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zhai, Ling, Anshu M. Roy, Ali Zamani, et al. "Abstract 4265: Bithionol as an inhibitor of tumor angiogenesis." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4265.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Baktash, Navid, Laura Fung, Amber Ablack, Desmond Pink, and John D. Lewis. "Abstract 5146: EGFL7 is a potent endogenous inhibitor of tumor angiogenesis." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-5146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Moriasi, Cate M., Satish Ramalingam, Dharmalingam Subramaniam, et al. "Abstract 1890: Curcumin inhibits tumor angiogenesis by suppressing protooncogene RBM3 expression." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1890.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhu, Li Ming, Dong-Mei Shi Shi, Qiang Dai, et al. "Abstract 4515: Tumor suppressor XAF1 inhibits hepatocellular carcinoma growth and angiogenesis." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4515.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Okamura, Heidi, Theresa Proia, Alisa Bell, et al. "Abstract 2990: Notch1 monoclonal antibody inhibits tumor growth and modulates angiogenesis." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2990.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Naiche, L. A., Bhairavi Swaminathan, Yu Kato, et al. "Abstract 1488: A novel Notch4 neutralizing antibody inhibits angiogenesis and tumor growth via a distinct mechanism from endothelial Notch1 inhibition." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-1488.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Tumoren. Angiogenese. Inhibitie"

1

Sato, J. D. Receptor Monoclonal Antibodies that Inhibit Tumor Angiogenesis. Defense Technical Information Center, 2001. http://dx.doi.org/10.21236/ada398146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sato, J. D. Receptor Monoclonal Antibodies that Inhibit Tumor Angiogenesis. Defense Technical Information Center, 1999. http://dx.doi.org/10.21236/ada383129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mukhopadhyay, Debabrata. Blocking Vascular Hyperpermeability, the Initiation Step of Tumor Angiogenesis Inhibits Mammary Tumor. Defense Technical Information Center, 2001. http://dx.doi.org/10.21236/ada400602.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Tumoren. Angiogenese. Inhibitie' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography